1. Scrip
  2. >>Conferences
  3. >>ASH

Autolus Shows Long Responses To CD19 CAR-T Therapy In Adult ALL Patients

Responses Longest With Low To Intermediate Tumor Burden

 
• By Mandy Jackson

Autolus presented event-free survival rates and other updated results at ASH from its Phase Ib/II FELIX clinical trial of obe-cel, a CD19 CAR-T therapy recently submitted for US FDA approval.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration

Autolus Therapeutics plc is awaiting US Food and Drug Administration acceptance of the biologics license application (BLA) it submitted in November for the CD19-targeting chimeric antigen receptor T-cell (CAR-T) therapy obecabtagene autoleucel (obe-cel) in the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), an indication currently only held by one CAR-T, Gilead Sciences, Inc.’s Tecartus. In the meantime, the company continues to report data from the Phase Ib/II FELIX clinical trial showing strong efficacy and better safety than competing CAR-T therapies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASH

Sweden’s Mendus Clears Regulatory Path For Vididencel Registration Trial

 
• By Kevin Grogan

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL

 
• By Alaric DeArment

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

 
• By Alaric DeArment

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class

 
• By Alaric DeArment

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.

More from Scrip

Merck KGaA Moves Closer To Sealing SpringWorks Buy

 
• By Kevin Grogan

The German group could pay $3.5bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.